PLATFORMS Signal 39
Abbott's Libre Duo is first FDA-authorized CGM to measure both glucose and ketones
↗
Abbott's new Libre Duo is the first FDA-authorized continuous glucose monitor that also tracks ketone levels, aiming to alert diabetics to ketoacidosis risk.
For engineers building health monitoring systems, this adds a second biomarker to a wearable sensor, complicating power, accuracy, and alert design. It also signals a trend where CGMs move beyond glucose into broader metabolic monitoring, raising the stakes for data reliability and user trust.
Written by elseif from the cluster below · every claim links back to a sourceThe three things worth knowing
The Libre Duo measures beta-hydroxybutyrate, a ketone, alongside glucose.
It lasts 10 days, requires a prescription, and uses the same app and smartwatch integration as Abbott's other CGMs.
The sensor is designed to act as a 'check engine light' for both glucose and ketone out-of-range alerts.
THE CLUSTER